[go: up one dir, main page]

PE20221004A1 - Conjugados de anticuerpos y farmacos anti-factor tisular y metodos relacionados - Google Patents

Conjugados de anticuerpos y farmacos anti-factor tisular y metodos relacionados

Info

Publication number
PE20221004A1
PE20221004A1 PE2021002191A PE2021002191A PE20221004A1 PE 20221004 A1 PE20221004 A1 PE 20221004A1 PE 2021002191 A PE2021002191 A PE 2021002191A PE 2021002191 A PE2021002191 A PE 2021002191A PE 20221004 A1 PE20221004 A1 PE 20221004A1
Authority
PE
Peru
Prior art keywords
cdr2
cdr1
cdr3
antibody
comprises seq
Prior art date
Application number
PE2021002191A
Other languages
English (en)
Inventor
Jan-Willem Theunissen
Allen G Cai
Thi-Sau Migone
Original Assignee
Iconic Therapeutics Inc
Zymeworks Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iconic Therapeutics Inc, Zymeworks Inc filed Critical Iconic Therapeutics Inc
Publication of PE20221004A1 publication Critical patent/PE20221004A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

El presente documento define un conjugado anticuerpo y farmaco que comprende: a. una proteina de union al antigeno (Ab) que se une al domino extracelular del factor tisular (TF) humano (SEQ ID n.º: 810), donde el Ab comprende una VHCDR1, una VH-CDR2, una VH-CDR3, una VL-CDR1, una VL-CDR2 y una VLCDR3, donde i. la VH-CDR1 comprende la SEQ ID n.°: 872, la VH-CDR2 comprende la SEQ ID n.°: 873, la VH-CDR3 comprende la SEQ ID n.°: 874, la VL-CDR1 comprende la SEQ ID n.°: 875, la VL-CDR2 comprende la SEQ ID n.°: 876 y la VL-CDR3 comprende la SEQ ID n.°: 877, ii. la VH-CDR1, la VH-CDR2, la VH-CDR3, la VL-CDR1, la VL-CDR2 y la VLCDR3 son del anticuerpo designado 25A3, iii. la VH-CDR1, la VH-CDR2, la VH-CDR3, la VL-CDR1, la VL-CDR2 y la VLCDR3 son del anticuerpo designado 25A, iv. la VH-CDR1, la VH-CDR2, la VH-CDR3, la VL-CDR1, la VL-CDR2 y la VLCDR3 son del anticuerpo designado 25A5, v. VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2 y VL-CDR3 son del anticuerpo designado 25A5-T o vi. VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2 y VL-CDR3 son del anticuerpo designado 25G1; y b. una o mas fracciones de toxinas y conectores representados por la Formula IV, en donde; X es -C(O)NHCH(CH2(R2 ))-+ , donde y + representan los respectivos puntos de union, como se indica en la Formula IV, o X esta ausente; L es un conector; ! representa el punto de union de L con el Ab, donde L se une al Ab mediante un enlace covalente; R1 se selecciona del grupo que consiste en ( ) donde # y % representan los respectivos puntos de union, como se indica en la Formula IV y R2 es fenilo. En el presente documento se proporcionan anticuerpos que se unen especificamente al factor tisular (TF) humano, conjugados de anticuerposfarmacos (ADC) antiTF y composiciones que comprenden a los anticuerpos o ADC.
PE2021002191A 2019-07-03 2020-07-02 Conjugados de anticuerpos y farmacos anti-factor tisular y metodos relacionados PE20221004A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962870644P 2019-07-03 2019-07-03
PCT/US2020/040711 WO2021003399A1 (en) 2019-07-03 2020-07-02 Anti-tissue factor antibody-drug conjugates and related methods

Publications (1)

Publication Number Publication Date
PE20221004A1 true PE20221004A1 (es) 2022-06-15

Family

ID=74100836

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021002191A PE20221004A1 (es) 2019-07-03 2020-07-02 Conjugados de anticuerpos y farmacos anti-factor tisular y metodos relacionados

Country Status (21)

Country Link
US (1) US20220257789A1 (es)
EP (1) EP3994150A4 (es)
JP (1) JP7709636B2 (es)
KR (1) KR20220029724A (es)
CN (1) CN114222752B (es)
AR (1) AR119346A1 (es)
AU (1) AU2020299398C9 (es)
BR (1) BR112021025720A2 (es)
CA (1) CA3141428A1 (es)
CL (2) CL2021003414A1 (es)
CO (1) CO2022001083A2 (es)
CR (1) CR20220047A (es)
DO (1) DOP2021000268A (es)
EA (1) EA202193309A1 (es)
EC (1) ECSP22007981A (es)
IL (1) IL289138A (es)
MX (1) MX2021015974A (es)
PE (1) PE20221004A1 (es)
PH (1) PH12021553289A1 (es)
TW (1) TWI879780B (es)
WO (1) WO2021003399A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020007077A (es) 2018-01-04 2020-10-28 Iconic Therapeutics Inc Anticuerpos anti-factor tisular, conjugados anticuerpo-farmaco y metodos relacionados.
WO2023137399A2 (en) * 2022-01-12 2023-07-20 Iconic Therapeutics Llc Inflammatory disease treatment using anti-tissue factor antibodies
CA3244292A1 (en) * 2022-02-24 2025-04-29 Evopoint Biosciences Co., Ltd. ANTIBODIES, DRUG CONJUGATES AND THEIR USES
WO2023172951A1 (en) * 2022-03-09 2023-09-14 Exelixis, Inc. Methods of treating solid tumors with anti-tissue factor antibody-drug conjugates
US20250276077A1 (en) * 2022-04-05 2025-09-04 Immunome, Inc. Epha2 antibodies
CN116143929B (zh) * 2023-02-03 2023-08-01 北京基科晟斯医药科技有限公司 抗重组人凝血因子VIIa-Fc融合蛋白的抗体及其应用
CN116789837B (zh) * 2023-03-24 2024-02-23 山西纳安生物科技股份有限公司 一种抗组织因子人源化抗体及制备的抗体偶联药物和应用
CN118772282A (zh) * 2023-04-10 2024-10-15 复旦大学 靶向组织因子的纳米抗体及偶联物的制备方法和用途
WO2024222868A1 (zh) * 2023-04-28 2024-10-31 江苏恒瑞医药股份有限公司 抗tf抗体和抗tf抗体-药物偶联物及其医药用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2802782C (en) * 2010-06-15 2018-03-13 Genmab A/S Human antibody drug conjugates against tissue factor
US10450378B2 (en) * 2014-09-17 2019-10-22 Zymeworks Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
CA2981851A1 (en) * 2015-04-07 2016-10-13 Alector Llc Anti-sortilin antibodies and methods of use thereof
MA49950A (fr) * 2017-08-25 2020-07-01 Five Prime Therapeutics Inc Anticorps anti-b7-h4 et leurs procédés d'utilisation
SG11202003713TA (en) * 2017-11-02 2020-05-28 Genmab As Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer
EP3717069A1 (en) * 2017-11-27 2020-10-07 Purdue Pharma L.P. Humanized antibodies targeting human tissue factor
MX2020007077A (es) * 2018-01-04 2020-10-28 Iconic Therapeutics Inc Anticuerpos anti-factor tisular, conjugados anticuerpo-farmaco y metodos relacionados.
TWI841554B (zh) * 2018-03-21 2024-05-11 丹麥商珍美寶股份有限公司 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法
KR20230028492A (ko) * 2020-06-29 2023-02-28 젠맵 에이/에스 항-조직 인자 항체-약물 접합체 및 암의 치료에서의 그의 용도

Also Published As

Publication number Publication date
CA3141428A1 (en) 2021-01-07
TW202116357A (zh) 2021-05-01
BR112021025720A2 (pt) 2022-06-21
CL2024003094A1 (es) 2025-02-07
WO2021003399A1 (en) 2021-01-07
IL289138A (en) 2022-02-01
PH12021553289A1 (en) 2022-08-01
DOP2021000268A (es) 2022-08-15
AU2020299398A1 (en) 2022-02-24
AU2020299398C9 (en) 2026-01-22
CR20220047A (es) 2022-06-23
EP3994150A4 (en) 2023-08-02
CN114222752A (zh) 2022-03-22
US20220257789A1 (en) 2022-08-18
CL2021003414A1 (es) 2022-09-09
JP2022538908A (ja) 2022-09-06
EP3994150A1 (en) 2022-05-11
KR20220029724A (ko) 2022-03-08
AR119346A1 (es) 2021-12-09
ECSP22007981A (es) 2022-05-31
AU2020299398C1 (en) 2025-10-02
EA202193309A1 (ru) 2022-03-28
MX2021015974A (es) 2022-04-26
JP7709636B2 (ja) 2025-07-17
CO2022001083A2 (es) 2022-05-20
CN114222752B (zh) 2025-11-14
TWI879780B (zh) 2025-04-11

Similar Documents

Publication Publication Date Title
PE20221004A1 (es) Conjugados de anticuerpos y farmacos anti-factor tisular y metodos relacionados
CN111867630B (zh) 靶向cldn18.2的抗体、双特异性抗体、adc和car及其应用
JP6727379B2 (ja) Ｈｅｒ２を標的とする二重特異性抗原結合性コンストラクト
CA2964830C (en) Anti-tim3 antibodies and methods of use
ES2784685T3 (es) Productos conjugados de anticuerpo-fármaco específicos de AXL para el tratamiento del cáncer
DK3102606T3 (en) ANTIBODY MEDICINAL CONJUGATES AND IMMUNTOXINES
UA116874C2 (uk) Імунокон'югат анти-мезотеліну
PE20091112A1 (es) Anticuerpos anti-tenb2 producidos por ingenieria de cisteina y conjugados de farmaco y anticuerpo
JP2024500242A (ja) 腫瘍特異的クローディン１８．２抗体と薬物との複合体
PH12020500417A1 (en) Anti-efgr antibody drug conjugates (adc) and uses thereof
JP6872482B2 (ja) Ｈｅｒ２を標的とする二重特異性抗原結合性構築物の使用方法
ES2633297T3 (es) Anticuerpos monoclonales al factor básico de crecimiento de fibroblastos
CO6290705A2 (es) Anticuerpos monoclonales aislados o porciones de union a antigenos, que se unen especificamente a la integrina alfa 5-beta1, y composiciones farmaceuticamente aceptables de los mismos
CN104755499B (zh) 结合HER3 β-发夹和HER4 β-发夹的抗HER3/HER4抗原结合蛋白
BRPI0719762B8 (pt) anticorpo humano isolado, composição, polinucleotídeo isolado, vetor de expressão, microrganismo isolado, método para fabricação de um anticorpo, e, uso de um anticorpo
PE20090368A1 (es) Anticuerpos anti-igf
JP2023509402A (ja) 新規抗ＦＧＦＲ２ｂ抗体
PE20220217A1 (es) Anticuerpos humanizados contra la region de la cadena beta de la 9na familia trbv9 del tcr humano, y sus metodos de uso
CA2930599A1 (en) Compounds to fibroblast growth factor receptor-3 (fgfr3) and therapeutic uses
PE20221459A1 (es) Conjugados anticuerpo-farmaco dirigido a claudina 18.2
JP2023508173A (ja) 新規抗ＦＧＦＲ２ｂ抗体
PE20220566A1 (es) ANTICUERPOS DE UNION A VISTA A pH ACIDO
PE20251880A1 (es) Novedosos anticuerpos anti-napi2b y conjugados-anticuerpo-droga basados en ellos, metodos terapeuticos y usos de los mismos
WO2020071881A1 (ko) Pdgf 수용체에 대한 항체 및 이의 용도
CN117440970A (zh) 抗nectin-4抗体及其用途